John Kitchens, MD, is joined by Peter Kaiser, MD, to discuss higher molar dose and its translation into clinical practice. They also discussed the challenges they face in treating patients with higher molar doses, including insurance limitations, safety concerns and convincing insurance carriers to switch to a new dose. They shared clinical pearls for helping patients transition to a higher dose.
Increasing aflibercept dose for longer drug duration in eyes.
Drug half-life and dosing for anti-VEGF treatments in ophthalmology.
Accelerating aflibercept dosing intervals for wet AMD patients.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.